NetworkNewsBreaks – QSAM Biosciences Inc. (QSAM)
Post# of 51
(Total Views: 249)
Posted On: 07/28/2022 4:40:04 PM
NetworkNewsBreaks – QSAM Biosciences Inc. (QSAM) Targeting Significant Unmet Medical Need with CycloSam(R)
QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone. “QSAM is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its proprietary radiopharmaceutical technology: CycloSam(R),” a recent article reads. “This is an important milestone for QSAM,” said the company’s co-founder and CEO Douglas R. Baum. “Successfully treating patients with primary or secondary bone cancer remains an area of significant unmet medical need and a goal for CycloSam(R).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone. “QSAM is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its proprietary radiopharmaceutical technology: CycloSam(R),” a recent article reads. “This is an important milestone for QSAM,” said the company’s co-founder and CEO Douglas R. Baum. “Successfully treating patients with primary or secondary bone cancer remains an area of significant unmet medical need and a goal for CycloSam(R).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)